ASP Isotopes Inc.
As of Oct 22, 2026, ASP Isotopes is in Stage 4, the downtrend phase, now in week 14 (since Jul 22, 2026). It closed at $2.09, 80.6% below its 52-week high and below its 200-day average, which is falling.
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ASPI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ASPI among Specialty Chemicals59th of 62 by relative strength
All 62 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | SSL | Stage 2 · wk 7 | 98 | +22.2% |
| 2 | ALTO | Stage 4 · wk 4 | 98 | −3.8% |
| 3 | CLMT | Stage 2 · wk 58 | 97 | −9.3% |
| 4 | KRO | Stage 2 · wk 10 | 90 | −9.4% |
| 5 | LYB | Stage 2 · wk 7 | 87 | +9.0% |
| 6 | ASH | Stage 2 · wk 20 | 86 | +6.6% |
| 7 | IFF | Stage 2 · wk 21 | 85 | +9.5% |
| 8 | KOP | Stage 3 · wk 4 | 85 | −11.9% |
| …59 | ASPI | Stage 4 · wk 14 | 12 | −30.6% |
ASP Isotopes: quick answers
What stage is ASP Isotopes in?
As of Oct 22, 2026, ASP Isotopes (ASPI) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 22, 2026 and is in week 14. What the four stages mean
Is ASP Isotopes in an uptrend?
No. ASP Isotopes is in a Stage 4 downtrend. It trades 58.2% below its 200-day average, which is falling.
How far is ASP Isotopes from its 52-week high?
ASP Isotopes closed at $2.09 on Oct 22, 2026, 80.6% below its 52-week high of $10.76. Its 52-week low is $2.03.
How has ASP Isotopes performed over the past year?
As of Oct 22, 2026, ASP Isotopes is down 78.3% over the past year and down 62.9% so far in 2026.
Which sector and industry is ASP Isotopes in?
ASP Isotopes is in the Specialty Chemicals industry, part of the Materials sector.
About this companyMaterials· Specialty Chemicals
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.